BPC-157 vs TB-500

BPC-157

A 15-amino-acid stretch lifted from a protein in human gastric juice. Best-known use is soft-tissue repair, with a quieter second life as a gut-healing protocol.

Best for

Best when you have a specific injury you can inject near (tendon, ligament, joint, gut). Site proximity is the strongest part of the data.

TB-500

A synthetic fragment of Thymosin Beta-4 used for systemic tissue repair. Sister peptide to BPC-157, but where BPC works locally, TB-500 spreads.

Best for

Best when the issue is systemic — multiple small injuries, post-surgical full-body recovery, generalised training overuse. No specific site to target.

BPC-157

Dozens of rodent and rat studies, mostly from a single Croatian research group (Sikiric and colleagues) that has been investigating this peptide since the 1990s. The replication base outside that group is thin. No completed human RCTs are in the public literature. Use anecdotal-plus-animal as your evidence floor, not as a substitute for the clinical trials that have not been done.

TB-500

Animal data is substantial — TB-500's parent protein Thymosin Beta-4 has been studied in wound healing, cardiac repair, and neural regeneration for decades. The 2012 Goldstein and Hannappel review covers the preclinical body of work. Human data is essentially absent: a small Phase 2 trial in dry-eye disease (RegeneRx) showed signal but didn't lead to approval, and the racehorse-doping literature is informative but not human-clinical. Use anecdotal-plus-animal as your evidence floor, not as a substitute for the missing human RCTs.